A Randomized, Open-Label, 2-Period, Crossover Trial to Assess the Relative Bioavailability of 80 mg LY03005 After Single Dose Administration to Healthy Subjects Under Fed Versus Fasted Conditions
Latest Information Update: 07 Aug 2019
At a glance
- Drugs Toludesvenlafaxine (Primary)
- Indications Major depressive disorder
- Focus Pharmacokinetics
- Sponsors Luye Pharma Group
Most Recent Events
- 05 Aug 2019 Status changed from recruiting to completed.
- 04 Feb 2019 New trial record